Market Valuation & Earnings Multiples
Market capitalization, P/E ratios, and enterprise value

Daré Bioscience, Inc. (DARE)
DARENASDAQHealthcareBiotechnology
As of Nov 20, 2026 close
Daré Bioscience has a $6.73M market cap and a −804.4% TTM net margin as of the Nov 20, 2026 close. Valuation, profitability, balance sheet, dividend and growth figures below.
Market value, earnings multiples, and pricing ratios
Market capitalization, P/E ratios, and enterprise value
Valuation ratios based on stock price
EV-based valuation multiples
Current price, 52-week range, and moving averages
Outstanding shares, float, and per-share metrics
Wall Street analyst ratings and 12-month price targets (90 days)
Profit margins, return metrics, and earnings analysis
Profitability margins across income statement
ROE, ROA, ROIC, and capital efficiency ratios
Trailing twelve months revenue and earnings
Operating cash flow and free cash flow metrics
Year-over-year growth metrics
Balance sheet analysis, debt ratios, and dividend metrics
Total assets and cash positions
Liabilities, debt, equity, and working capital
Liquidity, leverage, and debt coverage ratios
Dividend yield, payout ratios, and growth metrics
Earnings, FCF, buyback, and shareholder yields
Risk assessment and quality metrics
Source: Market prices and company fundamentals from financial filings. Data as of Nov 20, 2026. Data sources and methodology
As of the Nov 20, 2026 close, Daré Bioscience (DARE) trades at 4.9x TTM sales.
As of its most recent quarterly balance sheet, Daré Bioscience (DARE) has $7.23M of total debt and $12.62M in cash and securities, a net cash position of $5.38M. The current ratio is 0.99 and the quick ratio is 0.99.
Over the trailing twelve months Daré Bioscience (DARE) lost $10.99M on revenue of $1.37M, with a gross margin of −107.2%, an operating margin of −813.4%, a net margin of −804.4% and a free cash flow margin of −860.6%. On the same TTM basis, return on invested capital is −0.5% and return on assets is −49.1%.
Comparing the trailing twelve months with the twelve months before, Daré Bioscience (DARE)'s revenue grew 4366.5%.
Compare these multiples with other companies in the Healthcare sector.